Back to News
Market Impact: 0.2
MiNK Selected For ARPA-H Program To Advance Room-Temperature Cell Therapy
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
MiNK Therapeutics said its agenT-797 iNKT cell-therapy platform was selected for an ARPA-H-funded initiative focused on enabling room-temperature storage and transport of cell therapies. The selection could support technological advances that reduce cell-therapy logistics constraints, though no funding amount, clinical data, or financial impact was disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
INKT0.65
More News
- South Korea’s exports hit record high on AI boom
- RAM supply set to worsen, says Micron, as CEO celebrates ‘much higher’ prices
- Tencent leases 100,000 chips from Oracle for $7 bln- FT
- Asia stocks rise on chipmaker gains, soft U.S. inflation; Nikkei outperforms
- We're raising our Micron price target after an incredible quarter and robust guidance
- Why is Kioxia stock rallying today?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- State of Public Markets, June 2026: Higher for Longer Meets the AI Supercycle